Publicaciones en las que colabora con URSULA VERDALLÉS GUZMÁN (42)

2021

  1. Obesity related risk for chronic kidney disease progression and cardiovascular disease after propensity score matching

    Hipertension y Riesgo Vascular, Vol. 38, Núm. 2, pp. 63-71

  2. Riesgo relacionado con la obesidad para la progresión de insuficiencia renal crónica y enfermedad cardiovascular tras emparejamiento por puntaje de propensión

    Hipertensión y riesgo vascular, Vol. 38, Núm. 2, pp. 63-71

2020

  1. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

    Kidney International

  2. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists

    Nefrologia, Vol. 40, Núm. 1, pp. 66-74

  3. Progresión de la enfermedad renal crónica en pacientes con hipertensión resistente sometidos a 2 estrategias terapéuticas: intensificación con diuréticos de asa vs. antagonistas de la aldosterona

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 1, pp. 65-73

2019

  1. An old disease, a new diagnosis; A 49 year-old man with nephrotic syndrome

    Journal of Nephropathology, Vol. 8, Núm. 3

  2. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 2, pp. 128-139

  3. High convective volumes are associated with improvement in metabolic profile in diabetic patients on online haemodiafiltration

    Nefrologia, Vol. 39, Núm. 2, pp. 168-176

  4. Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 420-426

  5. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial

    Journal of Nephrology, Vol. 32, Núm. 4, pp. 581-587

2018

  1. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)

    Cardiovascular Drugs and Therapy, Vol. 32, Núm. 3, pp. 255-263

  2. Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass

    Nefrologia, Vol. 38, Núm. 1, pp. 73-78

  3. Impact of anticoagulation and platelet antiaggregation on anaemia and haemorragic events in patients with chronic kidney disease stages 3 and 4

    Medicina Clinica, Vol. 151, Núm. 12, pp. 476-480

  4. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a nephrology outpatient clinic

    Nefrologia, Vol. 38, Núm. 4, pp. 373-379

  5. Impacto de la aplicación del 8.o JNC y de las guías KDIGO-2013 en el control de la hipertensión arterial y los lípidos en una consulta de Nefrología

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 38, Núm. 4, pp. 379-385

2017

  1. Cardiovascular risk prediction in chronic kidney disease patients

    Nefrologia, Vol. 37, Núm. 3, pp. 293-300

  2. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 125, pp. 8-13

2016

  1. Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease

    Nefrologia, Vol. 36, Núm. 5, pp. 523-529

2015

  1. Allopurinol and progression of CKD and cardiovascular events: Long-term follow-up of a randomized clinical trial

    American Journal of Kidney Diseases, Vol. 65, Núm. 4, pp. 543-549

  2. Interarm systolic blood pressure as a predictor of cardiovascular events in patients with chronic kidney disease

    Nephrology Dialysis Transplantation, Vol. 30, Núm. 5, pp. 801-806